相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2-breast cancer and is associated with inferior outcomes
Matthew Mills et al.
JOURNAL OF GERIATRIC ONCOLOGY (2021)
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
Riyao Yang et al.
NATURE COMMUNICATIONS (2021)
Association of Galectin 9 Expression with Immune Cell Infiltration, Programmed Cell Death Ligand-1 Expression, and Patient's Clinical Outcome in Triple-Negative Breast Cancer
Mi-Ha Ju et al.
BIOMEDICINES (2021)
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression
Benedetta Pellegrino et al.
MOLECULAR DIAGNOSIS & THERAPY (2021)
Identification of Tumor Microenvironment-Related Prognostic Biomarkers in Luminal Breast Cancer
Yanyan Wang et al.
FRONTIERS IN GENETICS (2020)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
Stephen J. Luen et al.
LANCET ONCOLOGY (2017)
Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
Barbara Ingold Heppner et al.
CLINICAL CANCER RESEARCH (2016)
The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
Yan Mao et al.
PLOS ONE (2016)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node-Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX
Otto Metzger-Filho et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cell Surface Galectin-9 Expressing Th Cells Regulate Th17 and Foxp3+ Treg Development by Galectin-9 Secretion
Souichi Oomizu et al.
PLOS ONE (2012)
Galectin-9 regulates T helper cell function independently of Tim-3
Ee W. Su et al.
GLYCOBIOLOGY (2011)
TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
William D. Hastings et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
The aging of the immune system
Daniela Weiskopf et al.
TRANSPLANT INTERNATIONAL (2009)
Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer
A Irie et al.
CLINICAL CANCER RESEARCH (2005)
分享论文
